| Title |
Bevacizumab: A Review of Its Use in Advanced Cancer
|
|---|---|
| Published in |
Drugs, October 2014
|
| DOI | 10.1007/s40265-014-0302-9 |
| Pubmed ID | |
| Authors |
Gillian M. Keating |
| Abstract |
The humanized monoclonal antibody bevacizumab (Avastin(®)) has been available in the EU since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous non-small cell lung cancer, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. Results of these studies are supported by the findings of routine oncology practice studies conducted in real-world settings. The tolerability profile of bevacizumab is well defined and adverse events associated with its use (e.g. hypertension, proteinuria, haemorrhage, wound healing complications, arterial thromboembolism, gastrointestinal perforation) are generally manageable. In conclusion, bevacizumab remains an important option for use in patients with advanced cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 159 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 159 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 30 | 19% |
| Student > Bachelor | 28 | 18% |
| Student > Ph. D. Student | 26 | 16% |
| Researcher | 12 | 8% |
| Other | 10 | 6% |
| Other | 21 | 13% |
| Unknown | 32 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 24% |
| Biochemistry, Genetics and Molecular Biology | 21 | 13% |
| Agricultural and Biological Sciences | 21 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 7% |
| Chemistry | 6 | 4% |
| Other | 20 | 13% |
| Unknown | 42 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2021.
All research outputs
#4,508,465
of 22,766,595 outputs
Outputs from Drugs
#641
of 3,251 outputs
Outputs of similar age
#51,451
of 255,778 outputs
Outputs of similar age from Drugs
#10
of 38 outputs
Altmetric has tracked 22,766,595 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,251 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,778 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.